Market Cap: $932.31M
RI
Rigel Pharmaceuticals, Inc.
RIGL
NASDAQUSD
Market Cap: $932.31M
Rigel Pharmaceuticals Reports Promising Phase 1/2 Results for Pralsetinib in Lung Cancer Treatment Rigel Pharmaceuticals, a biotechnology company dedicated to addressing hematologic disorders and canc…
Rigel Pharmaceuticals Reports Positive Growth Amid Financial Loss in Q4 Earnings Rigel Pharmaceuticals (NASDAQ:RIGL) announces its Q4 earnings for the fiscal year ending in 2026, demonstrating notable…
Rigel Pharmaceuticals Shows Resilience in Recent Earnings Report Amid Strategic Pipeline Advancements Rigel Pharmaceuticals, known for its focus on developing novel therapies for rare diseases, recent…
Rigel Pharmaceuticals Reports Solid Growth Amid Challenges Rigel Pharmaceuticals, renowned for its focus on developing therapies for rare diseases, releases its quarterly earnings report on March 3, 2…
Rigel taps industry veteran to drive commercial expansion Board addition intended to accelerate product growth and in‑licensing Rigel Pharmaceuticals appoints Michael P. Miller to its board, a move th…
Commercial veteran joins Rigel’s board to steer portfolio growth Rigel Pharmaceuticals appoints Michael P. Miller to its board, naming a commercial executive with more than four decades of industry ex…
Rigel taps veteran commercial executive to drive growth initiatives Rigel Pharmaceuticals appoints Michael P. Miller to its board of directors, bolstering commercial capacity as the South San Francisc…
Rigel Pharmaceuticals Reports Strong Revenue Growth and Focus on Clinical Advancements Rigel Pharmaceuticals, Inc. demonstrates impressive financial performance in its preliminary fourth quarter of 20…
Rigel Pharmaceuticals Reports Strong Revenue Growth and Advances Clinical Trials Rigel Pharmaceuticals, Inc., a biotechnology company specializing in hematologic disorders and cancer therapies, announ…
Rigel Pharmaceuticals Strengthens Talent Base with New Employee Incentives Rigel Pharmaceuticals, Inc., a biotechnology firm based in South San Francisco, California, takes a significant step to enhan…
Rigel Pharmaceuticals Strengthens Workforce to Drive Innovation in Hematologic Disorders and Cancer Treatment Rigel Pharmaceuticals, Inc. recently announces a strategic move to bolster its workforce b…
Rigel Pharmaceuticals Advances Treatment for Lower-Risk Myelodysplastic Syndrome with R289 Rigel Pharmaceuticals, Inc. has unveiled promising preliminary results from its ongoing Phase 1b study of R28…
### Rigel Pharmaceuticals Advances in Treatment for Lower-Risk Myelodysplastic Syndromes Rigel Pharmaceuticals, Inc., a biotechnology company specializing in hematologic disorders and cancer, reports…
Rigel Pharmaceuticals Advances in MDS Treatment with R289 Data Rigel Pharmaceuticals, Inc. reports encouraging preliminary efficacy results from its Phase 1b study of R289, an oral prodrug of R835, ai…
### Rigel Pharmaceuticals Enhances Investor Engagement Through Upcoming Presentation Rigel Pharmaceuticals, Inc. is set to present an overview of its innovative work at the Piper Sandler 37th Annual H…
Rigel Pharmaceuticals Enhances Investor Engagement at Upcoming Healthcare Conference Rigel Pharmaceuticals, Inc., a biotechnology company based in South San Francisco, showcases its commitment to adva…
Rigel Pharmaceuticals Set to Present at Healthcare Conference, Highlighting Commitment to Innovation Rigel Pharmaceuticals, Inc., a leading biotechnology company based in South San Francisco, announce…
Rigel Pharmaceuticals Prepares for Key Presentation at Jefferies Global Healthcare Conference Rigel Pharmaceuticals, Inc., based in South San Francisco, is set to showcase its advancements in hematolo…
Rigel Pharmaceuticals Advances Hematologic and Cancer Therapies Rigel Pharmaceuticals, Inc., a biotechnology firm based in South San Francisco, is making strides in the development of innovative treat…
Rigel Pharmaceuticals: Advancing Innovative Therapies for Hematologic Disorders and Cancer Rigel Pharmaceuticals, Inc., based in South San Francisco, California, is at the forefront of biotechnology,…
Rigel Pharmaceuticals Advances Innovative Treatments for Rare Diseases Rigel Pharmaceuticals, a leader in the development of therapies for rare diseases, showcases its commitment to advancing medical…
Rigel Pharmaceuticals Enhances Its Pipeline with Promising Drug Developments In a significant move for Rigel Pharmaceuticals, the company continues to advance its robust pipeline of innovative treatme…
Rigel Pharmaceuticals Prepares to Showcase Promising Data at ASH Annual Meeting Rigel Pharmaceuticals, Inc. is gearing up for a significant presentation at the 67th American Society of Hematology (ASH…
Rigel Pharmaceuticals Prepares for ASH Annual Meeting Presentation on R289 Rigel Pharmaceuticals, Inc. is poised to showcase its advancements in hematologic disorders at the upcoming 67th American Soc…
Rigel Pharmaceuticals Advances R289 for Myelodysplastic Syndrome Treatment Rigel Pharmaceuticals, Inc. is making significant strides in the development of its investigational drug R289, a dual inhibit…